Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
Progenity, Inc. (Nasdaq: PROG) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Progenity, Inc. (Nasdaq: PROG) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference with a pre-recorded presentation available on January 10, 2022. The presentation will be accessible at 7 a.m. Eastern / 4 a.m. Pacific on the conference website and on Progenity's Investor section.
Progenity focuses on oral biotherapeutics and aims to innovate in gastrointestinal and women's health through a multi-omics approach for precise diagnostics and localized treatment solutions.
Details
News Market Reaction – PROG
The recorded move for PROG in the trading session of this news was +7.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022.
A link to the presentation will also be available at the same time in the Investors section of the company’s website at progenity.com/presentations.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the fields of women’s health, gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.
Investor Contact:
Robert Uhl
Managing Director, ICR Westwicke
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(619) 743-6294
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.